There is no cure for Rett syndrome. However, the treatment landscape has shifted significantly in recent years, with the first FDA-approved medication arriving in 2023 and multiple gene therapy trials now underway that aim to address the root genetic cause. While none of these approaches can yet reverse the condition, they represent the closest science has come to meaningful disease modification.
What Causes Rett Syndrome
Rett syndrome results from mutations in the MECP2 gene, which produces a protein essential for brain cells to mature and function properly. Without enough of this protein, neurons don’t develop the way they should, leading to a distinctive pattern of developmental regression that typically begins between 6 and 18 months of age.
The hallmark of Rett syndrome is a period of regression after what appears to be normal early development. Children lose purposeful hand use and spoken language (or babbling, if that was the skill they’d reached). Repetitive hand movements like wringing, clapping, or mouthing develop, and walking becomes impaired or doesn’t develop at all. Slowing head growth is often one of the earliest signs. After this regression period, some stabilization occurs, but the lost skills generally don’t fully return.
The First FDA-Approved Treatment
In 2023, the FDA approved trofinetide (brand name Daybue) for treating Rett syndrome in children age two and older. This was a landmark moment: the first drug ever approved specifically for this condition. Trofinetide doesn’t fix the underlying gene mutation, but it targets downstream effects in the brain.
In clinical trials, patients taking trofinetide showed statistically significant improvements compared to placebo on standardized measures of Rett syndrome severity and overall clinical improvement after 12 weeks. The improvements were modest but meaningful for a condition that previously had no approved pharmacological treatment at all.
The main drawback is side effects, particularly gastrointestinal ones. In trials, 82% of patients on trofinetide experienced diarrhea, compared to 20% on placebo. Vomiting affected 29% (versus 12% on placebo). Other reported side effects included fever, decreased appetite, fatigue, and anxiety. These rates are high enough that managing side effects becomes part of the treatment experience for many families.
Gene Therapy Trials Targeting the Root Cause
The most promising research aims to correct what’s actually broken: the faulty MECP2 gene. Several gene therapy programs are in clinical trials, each taking a slightly different approach.
Taysha Gene Therapies is running a Phase 1/2 trial (called REVEAL) testing TSHA-102, a one-time injection delivered into the spinal fluid. The study is evaluating two dose levels in pediatric patients and tracking safety and efficacy over 52 weeks. Neurogene’s NGN-401 program has advanced further, reaching a pivotal Phase 3 trial (called Embolden) with an estimated completion date of late 2029. That trial measures success by whether patients gain at least one developmental milestone from a defined list of 28 skills, verified through video recordings reviewed by independent raters.
What makes gene therapy for Rett syndrome particularly tricky is that too much MECP2 protein is also harmful. The gene needs to produce just the right amount. Neurogene’s approach uses a proprietary system to regulate how much protein the delivered gene produces, attempting to thread that needle.
Why Researchers Believe Reversal Is Possible
One of the most encouraging findings in Rett syndrome research comes from animal studies showing that the neurological damage is not permanent in the way scientists once assumed. In mouse models, reactivating the MECP2 gene later in life reversed neurological abnormalities, even after symptoms had already appeared. This suggests the brain cells aren’t destroyed by the mutation; they’re impaired in a way that can potentially be corrected.
This is the scientific rationale driving gene therapy development. If the protein can be restored to adequate levels, there’s reason to believe at least some symptoms could improve, even in patients who have been living with the condition for years.
RNA Editing: A Different Genetic Strategy
Beyond traditional gene replacement, researchers are exploring RNA editing as an alternative approach. Rather than delivering a new copy of the gene, RNA editing repairs the instructions the existing gene sends out. The advantage is precision: because it works on the gene’s messaging system rather than adding a second copy, the protein levels should never exceed what the body would naturally produce. This sidesteps the overexpression problem that makes standard gene therapy so challenging for Rett syndrome.
A 2022 study published in the Proceedings of the National Academy of Sciences demonstrated that targeted RNA editing in the brainstem of mice with Rett syndrome alleviated respiratory dysfunction, one of the condition’s most dangerous symptoms. This remains at the proof-of-concept stage, with no human trials yet, but it opens a second path toward genetic correction.
Managing Symptoms Now
While families wait for curative therapies, current treatment focuses on managing the symptoms that most affect quality of life. Seizures are one of the biggest challenges. Multiple anti-seizure medications are used, with effectiveness varying considerably between individuals. Some studies found certain medications effective in most patients tested, while the same drug showed no benefit in a different group. Finding the right medication often requires trial and adjustment.
Communication is another major focus. Because Rett syndrome takes away hand use and speech but often preserves visual attention, eye-tracking technology has become an important tool. These devices allow patients to communicate by looking at options on a screen. In studies of patients using eye-tracking systems with ongoing support from communication therapists, all participants made measurable progress on individualized communication goals. Parents reported improvements in their children’s psychosocial functioning as well, suggesting the benefits extend beyond the practical ability to point at symbols on a screen.
Physical therapy, occupational therapy, and nutritional support also play central roles. Feeding difficulties and swallowing dysfunction are common and can lead to aspiration pneumonia, which is the most frequent cause of death in Rett syndrome. Careful management of nutrition and swallowing is not just about comfort; it directly affects long-term survival.
Life Expectancy and Long-Term Outlook
Most individuals with Rett syndrome survive into middle age, with many living into their 40s and 50s. Recent data suggest survival may be improving. The survival rate at age 25 is approximately 78%. The leading causes of death are cardiorespiratory complications and pneumonia, the latter often linked to swallowing difficulties that allow food or liquid into the lungs.
The outlook is better than many families initially fear when they receive the diagnosis. Rett syndrome is a serious, life-altering condition, but it is not rapidly progressive in the way some neurodegenerative diseases are. After the regression period, many individuals stabilize for decades. With the first approved medication now available and gene therapies advancing through clinical trials, the treatment landscape for Rett syndrome is more active than it has ever been.